Biogen Idec: 4 Different Insiders Have Sold Shares This Year

Jan.20.14 | About: Biogen Inc. (BIIB)

In this article, I will feature one biotech stock that has seen intensive insider selling during the last 30 days. Intensive insider selling can be defined by the following three criteria:

  1. The stock was sold by three or more insiders within one month.
  2. The stock was not purchased by any insiders in the month of intensive selling.
  3. At least two sellers decreased their holdings by more than 10%.

Biogen Idec (NASDAQ:BIIB) discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally.

Click to enlarge

Insider selling during the last 30 days

Here is a table of Biogen Idec's insider-trading activity during the last 30 days by insider.

Name Title Trade Date Shares Sold Rule 10b5-1 Current Ownership Decrease In Ownership
Lynn Schenk Director Jan 15 1,000 Yes 6,425 shares 13.5%
William Young Director Jan 8 15,000 Yes 18,509 shares 44.8%
Robert Pangia Director Jan 6 6,250 Yes

14,003 shares + 6,250 options

23.6%
Stephen Sherwin Director Jan 2 5,500 Yes 3,960 shares + 16,675 options 21.0%
Click to enlarge

There have been 27,750 shares sold by insiders during the last 30 days. All these shares were sold pursuant to a Rule 10b5-1 plan.

SEC Rule 10b5-1 is a regulation enacted by the United States Securities and Exchange Commission (SEC) in 2000. The SEC states that Rule 10b5-1 was enacted in order to resolve an unsettled issue over the definition of insider trading, which is prohibited by SEC Rule 10b-5. After Rule 10b5-1 was enacted, the SEC staff publicly took the position that canceling a planned trade made under the safe harbor does not constitute insider trading, even if the person was aware of the inside information when canceling the trade. This staff interpretation raises the possibility that executives can exploit this safe harbor by entering into 10b5-1 trading plans before they have inside information while retaining the option to later cancel those plans based on inside information.

For example, a CEO of a company could call a broker on January 1 and enter into a plan to sell a particular quantity of shares of his company's stock on March 1, find out terrible news about his company on February 1 that will not become public until April 1, and then go forward with the March 1 sale anyway, saving himself from losing money when the bad news becomes public. Under the terms of Rule 10b5-1(b) this is insider trading because the CEO "was aware" of the inside information when he made the trade. But he can assert an affirmative defense under Rule 10b5-1(c), because he planned the trade before he learned the inside information.

In general, it is a safer way for an insider to sell shares pursuant to a Rule 10b5-1 trading plan than without it.

Insider selling by calendar month

Here is a table of Biogen Idec's insider-trading activity by calendar month.

Month Insider selling / shares Insider buying / shares
January 2014 27,750 0
December 2013 1,439 0
November 2013 7,239 0
October 2013 18,269 0
September 2013 147,715 0
August 2013 6,607 0
July 2013 2,239 0
June 2013 23,363 0
May 2013 83,448 0
April 2013 25,210 0
March 2013 65,153 0
February 2013 14,098 0
January 2013 0 0
Click to enlarge

There have been 422,530 shares sold, and there have been zero shares purchased by insiders since January 2013.

Financials

Biogen Idec reported the third-quarter financial results on October 28 with the following highlights:

Revenue $1.8 billion
GAAP net income $487.6 million
Cash $1.0 billion
Debt $698.3 million
Click to enlarge

Click to enlarge

(Source: Earnings presentation)

Outlook

Biogen Idec's full-year 2013 financial guidance is as follows:

Revenue growth 23% to 25%
Non-GAAP EPS $8.65-$8.85
GAAP EPS $7.50-$7.70
Click to enlarge

Click to enlarge

(Source: Earnings presentation)

Pipeline and upcoming milestones

Biogen Idec's approved products include Tecfidera, Tysabri, Avonex, Rituxan, and Fampyra. Biogen Idec has several product candidates in the pipeline.

Click to enlarge

(Source: Earnings presentation)

Biogen Idec's upcoming late stage pipeline events include the following.

Click to enlarge

(Source: Earnings presentation)

Competition

Biogen Idec's competitors include Teva Pharmaceutical Industries (NASDAQ:TEVA), GlaxoSmithKline (NYSE:GSK), and Pfizer (NYSE:PFE). Here is a table comparing these companies.

Company BIIB TEVA GSK PFE
Market Cap: 69.45B 36.80B 129.29B 202.01B
Employees: 5,950 45,948 99,488 78,400
Qtrly Rev Growth (yoy): 0.32 -0.01 -0.00 -0.02
Revenue: 6.38B 20.05B 42.44B 56.25B
Gross Margin: 0.89 0.53 0.70 0.81
EBITDA: 2.73B 5.67B 14.92B 24.62B
Operating Margin: 0.36 0.20 0.26 0.32
Net Income: 1.70B 419.00M 6.25B 10.68B
EPS: 7.12 0.49 2.54 3.62
P/E: 41.30 89.43 21.17 8.60
PEG (5 yr expected): 1.64 1.09 1.56 4.77
P/S: 10.98 1.85 3.03 3.59
Click to enlarge
Click to enlarge

Biogen Idec has the highest P/S ratio among these four companies.

Here is a table of these competitors' insider-trading activities during the last 12 months.

Company Insider buying / shares Insider selling / shares
GSK N/A N/A
PFE

0

1,428,368
TEVA N/A N/A
Click to enlarge

Only Biogen Idec has seen intensive insider selling during the last 30 days.

Conclusion

There have been four different insiders selling Biogen Idec, and there have not been any insiders buying Biogen Idec during the last 30 days. All four of these insiders decreased their holdings by more than 10%. Biogen Idec has an insider ownership of 0.10%.

Before entering short Biogen Idec, I would like to get a bearish confirmation from the Point and Figure chart. The two main reasons for the proposed short entry are relatively high P/S ratio, and the intensive insider-selling activity.

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.